Safety of Local Dental Anesthesia in Patients With Cardiac Channelopathies


Patients with cardiac channelopathies needing restorative dental treatment will be included in two sessions of the study, using local dental anesthetic: lidocaine 2% with epinephrine and lidocaine 2% without vasoconstrictor. The safety of the use of two cartridges (3.6 mL) will be evaluated. The patients will be their own control and will be assessed by Holter monitoring for 28 hours, blood pressure measurement and anxiety measuring.

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Crossover Assignment
    • Primary Purpose: Supportive Care
    • Masking: Double (Participant, Investigator)
  • Study Primary Completion Date: August 2018

Detailed Description

Patients of Heart Institute of the University of São Paulo with inherited cardiac channelopathies will be included, considering the criteria for inclusion and non-inclusion, after reading and signing the informed consent.

They will undergo dental restorative treatment in two sessions, in the morning period, with an interval of at least seven days (wash-out) between them, and the patients will be their own control.

In the first session, after randomization, patients will receive lidocaine 2% without vasoconstrictor (LSA) or lidocaine 2% with 1: 100,000 epinephrine (LCA) (cross-over), resulting in two conditions: with adrenaline and without adrenaline.

The randomization of the anesthetic solution will be performed by the main researcher, being blind to the performer researcher and to the patient.

The injected volume will be 3.6 mL (2 cartridges) of the anesthetic solution, using blocking technique of the inferior alveolar nerve.

The patients will be monitored by Holter for 28 hours starting one hour before the procedure, for registration and analysis of cardiac electrical activity during the two sessions. Blood pressure will be monitored with digital sphygmomanometer and anxiety will be measured with Facial Image Scale, both on three occasions: at the beginning of the baseline periods, before starting application of anesthesia and at the end of the proceedings. The results will be analyzed statistically.


  • Procedure: Dental restorative procedure
    • Infiltration of two cartridges (3.6 mL) of local anesthetics with 2% lidocaine with or without epinephrine 1:100,000, in two sessions with an interval of seven days between them, in oral mucosa in patients with cardiac channelopathies.

Arms, Groups and Cohorts

  • Active Comparator: Lidocaine with epinephrine
    • Application of local dental anesthesia with two cartridges (3,6 mL) of lidocaine 2% with epinephrine 1:100.000 for dental restorative procedures in patients with cardiac channelopathies.
  • Active Comparator: Lidocaine
    • Application of local dental anesthesia with two cartridges (3,6 mL) of lidocaine 2% without vasoconstrictor for dental restorative procedures in patients with cardiac channelopathies.

Clinical Trial Outcome Measures

Primary Measures

  • No sustained ventricular tachycardia
    • Time Frame: during dental procedures
    • No life-threatening arrhythmias and clinical signs and symptoms

Participating in This Clinical Trial

Inclusion Criteria

  • Patients with any channelopathies below, kept on optimal drug therapy, with or without ICD:

Brugada Syndrome, Long QT Syndrome and Catecholaminergic Polymorphic Ventricular Tachycardia

  • Dental caries or unsatisfactory restorations in the mandible, indicating restorative dental treatment

Exclusion Criteria

  • Patients allergic to lidocaine
  • Patients undergoing ICD therapy for less than three months
  • Patients with recurrent syncope in the last three months
  • Patients with sustained arrhythmias documented for less than 3 months
  • Have received epinephrine in the last 24 hours

Gender Eligibility: All

Minimum Age: 6 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • University of Sao Paulo General Hospital
  • Collaborator
    • Fundação de Amparo à Pesquisa do Estado de São Paulo
  • Provider of Information About this Clinical Study
    • Principal Investigator: Itamara Lucia Itagiba Neves, Principal Investigator – University of Sao Paulo General Hospital
  • Overall Official(s)
    • Itamara LI Neves, PhD, Principal Investigator, Instituto do Coração do HCFMUSP
    • Ana CG Oliveira, S, Study Chair, Instituto do Coração do HCFMUSP
    • Ricardo S Neves, PhD, Study Director, Instituto do Coração do HCFMUSP
    • Luciana Sacilotto, S, Study Chair, Instituto do Coração do HCFMUSP
    • Francisco CC Darrieux, PhD, Study Chair, Instituto do Coração do HCFMUSP
    • Maurício I Scanavacca, PhD, Study Director, Instituto do Coração do HCFMUSP
    • Denise Hachul, PhD, Study Chair, Instituto do Coração do HCFMUSP
    • Cesar J Gruppi, PhD, Study Director, Instituto do Coração do HCFMUSP


Amin AS, Asghari-Roodsari A, Tan HL. Cardiac sodium channelopathies. Pflugers Arch. 2010 Jul;460(2):223-37. doi: 10.1007/s00424-009-0761-0. Epub 2009 Nov 29. Review.

Kauferstein S, Kiehne N, Neumann T, Pitschner HF, Bratzke H. Cardiac gene defects can cause sudden cardiac death in young people. Dtsch Arztebl Int. 2009 Jan;106(4):41-7. doi: 10.3238/arztebl.2009.0041. Epub 2009 Jan 23. Review.

Pérusse R, Goulet JP, Turcotte JY. Contraindications to vasoconstrictors in dentistry: Part I. Cardiovascular diseases. Oral Surg Oral Med Oral Pathol. 1992 Nov;74(5):679-86. Review.

Groban L, Deal DD, Vernon JC, James RL, Butterworth J. Ventricular arrhythmias with or without programmed electrical stimulation after incremental overdosage with lidocaine, bupivacaine, levobupivacaine, and ropivacaine. Anesth Analg. 2000 Nov;91(5):1103-11.

Jowett NI, Cabot LB. Patients with cardiac disease: considerations for the dental practitioner. Br Dent J. 2000 Sep 23;189(6):297-302. Review.

Rochford C, Seldin RD. Review and management of the dental patient with Long QT syndrome (LQTS). Anesth Prog. 2009 Summer;56(2):42-8. doi: 10.2344/0003-3006-56.2.42. Review.

Buchanan H, Niven N. Validation of a Facial Image Scale to assess child dental anxiety. Int J Paediatr Dent. 2002 Jan;12(1):47-52.

Naftalin LW, Yagiela JA. Vasoconstrictors: indications and precautions. Dent Clin North Am. 2002 Oct;46(4):733-46, ix. Review.

Pallasch TJ. Vasoconstrictors and the heart. J Calif Dent Assoc. 1998 Sep;26(9):668-73, 676. Review.

Finder RL, Moore PA. Adverse drug reactions to local anesthesia. Dent Clin North Am. 2002 Oct;46(4):747-57, x. Review.

Goulet JP, Pérusse R, Turcotte JY. Contraindications to vasoconstrictors in dentistry: Part III. Pharmacologic interactions. Oral Surg Oral Med Oral Pathol. 1992 Nov;74(5):692-7. Review.

Brown RS, Rhodus NL. Epinephrine and local anesthesia revisited. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2005 Oct;100(4):401-8. Review.

Hersh EV, Giannakopoulos H. Beta-adrenergic blocking agents and dental vasoconstrictors. Dent Clin North Am. 2010 Oct;54(4):687-96. doi: 10.1016/j.cden.2010.06.009. Review.

Neves RS, Neves IL, Giorgi DM, Grupi CJ, César LA, Hueb W, Grinberg M. Effects of epinephrine in local dental anesthesia in patients with coronary artery disease. Arq Bras Cardiol. 2007 May;88(5):545-51. English, Portuguese.

Yagiela JA. Adverse drug interactions in dental practice: interactions associated with vasoconstrictors. Part V of a series. J Am Dent Assoc. 1999 May;130(5):701-9. Review.

Cáceres MT, Ludovice AC, Brito FS, Darrieux FC, Neves RS, Scanavacca MI, Sosa EA, Hachul DT. Effect of local anesthetics with and without vasoconstrictor agent in patients with ventricular arrhythmias. Arq Bras Cardiol. 2008 Sep;91(3):128-33, 142-7. English, Portuguese.

Theodotou N, Cillo JE Jr. Brugada syndrome (sudden unexpected death syndrome): perioperative and anesthetic management in oral and maxillofacial surgery. J Oral Maxillofac Surg. 2009 Sep;67(9):2021-5. doi: 10.1016/j.joms.2009.04.043.

Ackerman MJ, Khositseth A, Tester DJ, Hejlik JB, Shen WK, Porter CB. Epinephrine-induced QT interval prolongation: a gene-specific paradoxical response in congenital long QT syndrome. Mayo Clin Proc. 2002 May;77(5):413-21.

Wynn RL. Articaine 4% with 1:200,000 epinephrine: an acceptable option for patients with long QT syndrome. Gen Dent. 2007 May-Jun;55(3):176-8.

Middlehurst RJ, Gibbs A, Walton G. Cardiovascular risk: the safety of local anesthesia, vasoconstrictors, and sedation in heart disease. Anesth Prog. 1999 Fall;46(4):118-23.

Fujiki A, Nishida K, Mizumaki K, Nagasawa H, Shimono M, Inoue H. Spontaneous onset of torsade de pointes in long-QT syndrome and the role of sympathovagal imbalance. Jpn Circ J. 2001 Dec;65(12):1087-90.

Monteforte N, Napolitano C, Priori SG. Genetics and arrhythmias: diagnostic and prognostic applications. Rev Esp Cardiol (Engl Ed). 2012 Mar;65(3):278-86. doi: 10.1016/j.recesp.2011.10.008. Epub 2012 Jan 14. Review. English, Spanish.

Ernesto C, Cruz FE, Lima FS, Coutinho JL, Silva R, Urményi TP, Carvalho AC, Rondinelli E. Investigation of ion channel gene variants in patients with long QT syndrome. Arq Bras Cardiol. 2011 Mar;96(3):172-8. Epub 2011 Feb 4. English, Portuguese, Spanish.

Meyer JS, Mehdirad A, Salem BI, Kulikowska A, Kulikowski P. Sudden arrhythmia death syndrome: importance of the long QT syndrome. Am Fam Physician. 2003 Aug 1;68(3):483-8. Review. Erratum in: Am Fam Physician. 2004 May 15;69(10):2324.

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.